 |
answer text |
<p>The criteria and scoring system for reviewing the current listed drugs within the
Cancer Drugs Fund (CDF) is outlined in the published CDF Standard Operating Procedure
which is available at: www.england.nhs.uk/ourwork/pe/cdf/. These state that:</p><p>
</p><p> </p><p> </p><p>“Decisions will be based on the National Cancer Drugs Fund
Prioritisation Tool in conjunction with an assessment of median drug cost per patient.
This evaluation will be completed for each drug/indication under consideration and
will result in an overall score based on a number of factors, including:</p><p> </p><p>o
evidence of clinical benefit e.g. progression free survival (PFS) and overall survival
(OS)</p><p> </p><p>o quality of life (QOL)</p><p> </p><p>o toxicity</p><p> </p><p>o
unmet need</p><p> </p><p>o median drug cost per patient</p><p> </p><p> </p><p> </p><p>Drugs
on the National CDF List will be subject to an affordability test within the overall
CDF budget, being added or removed according to their relative aggregate score using
the National Cancer Drugs Fund Prioritisation Tool of clinical benefit in conjunction
with the assessment of drug cost per patient. Drugs whose aggregate score is below
the threshold applicable at the time will not be added/will be removed from the National
CDF List.”</p><p> </p><p> </p><p> </p><p>A copy is attached.</p><p> </p><p> </p><p>
</p><p>NHS England has advised that the Fund is re-prioritised on a regular basis
so that the resources available are used to the best benefit of patients.</p><p> </p><p>
</p><p> </p><p> </p>
|
|
